Aeglea Biotherapeutics

Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing for tumor cells. Aeglea’s first two programs utilize enzymes that degrade either the amino acid L-methionine (Met) or L-arginine (Arg) for use as therapy in oncology. Aeglea’s therapeutic strategy takes advantage of decades of clinical validation to leverage the genetic and epigenetic basis of tumor AA auxotrophy to identify patients likely to benefit from these molecules.
Type
Public
HQ
Austin, US
Founded
2013
Size (employees)
31 (est)+35%
Aeglea Biotherapeutics was founded in 2013 and is headquartered in Austin, US

Aeglea Biotherapeutics Office Locations

Aeglea Biotherapeutics has an office in Austin
Austin, US (HQ)
250 Barton Oaks Plaza One 901 S Mo Pac Expy

Aeglea Biotherapeutics Data and Metrics

Aeglea Biotherapeutics Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(21.7 m)

EBIT (FY, 2016)

(21.9 m)

Market capitalization (22-Jun-2017)

65 m

Closing share price (22-Jun-2017)

4

Cash (31-Dec-2016)

47.7 m
Aeglea Biotherapeutics's current market capitalization is $65 m.
FY, 2016

R&D expense

18.1 m

General and administrative expense

8.4 m

Operating expense total

26.5 m

EBIT

(21.9 m)

Interest income

244 k

Net Income

(21.7 m)
FY, 2016

Cash

47.7 m

Inventories

1.7 m

Current Assets

66.4 m

PP&E

599 k

Total Assets

67.1 m

Accounts Payable

168 k

Current Liabilities

4 m

Additional Paid-in Capital

108.2 m

Retained Earnings

(45.3 m)

Total Equity

63 m

Financial Leverage

1.1 x
FY, 2016

Net Income

(21.7 m)

Depreciation and Amortization

132 k

Accounts Receivable

(43.6 k)

Inventories

(96.1 k)

Accounts Payable

(8 k)

Cash From Operating Activities

(18.8 m)

Purchases of PP&E

(212 k)

Cash From Investing Activities

(12.1 m)

Cash From Financing Activities

49.4 m
Y, 2016

Financial Leverage

1.1 x

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development

3

Phase 1/2

1

Phase I Trials

2

Phase Approved

1

Aeglea Biotherapeutics Market Value History

Aeglea Biotherapeutics Company Life and Culture

You may also be interested in